The vaccine was found to generate a robust immune response in animals exposed to the vaccine with strong data indicating safety and efficacy, according to the study published recently in the journal Nature Communications. The results have been used to begin testing the vaccine in human trials in the United States with a Phase 3 trial that recently launched at UMSOM’s Center for Vaccine Development and Global Health (CVD).
U.S. drug maker Emergent BioSolutions began speeding up its acquisition of drug supplies beginning early last year, as the coronavirus outbreak was erupting in China. In addition to producing drugs like the opioid overdose-reversing Narcan nasal spray, the firm develops vaccines and antibody therapeutics and had scored lucrative contracts for key biodefense medicines over the decades.
The Center for Advancing Point of Care Technologies (CAPCaT) in Heart, Lung, Blood, and Sleep Disorders (U54HL143541) announces the 2021 solicitation of grant applications focused on developing, adapting, or validating point of care technologies that can be rapidly applied to heart, lung, blood, or sleep disorders, with additional interest in projects that incorporate complementary and integrative health approaches. We plan, based on the receipt of meritorious applications, to fund up to four awards of up to $100,000 over 12 months, with one or more award(s) focused on complementary and integrative health.
The Port Covington Development Team consisting of lead investors Sagamore Ventures and Goldman Sachs Urban Investment Group, and lead developer Weller Development Company, today announced that financing for the next development phase has been finalized. The capitalization totals more than $650 million, including approximately $137 million in Tax Increment Financing (TIF) bonds. The closing of the financing marks a significant milestone for one of the largest urban revitalization efforts in the country, signifying vertical construction is underway. In conjunction with the closings, the Port Covington Development Team funded more than $9 million to the South Baltimore 7 (SB7) Coalition, as part of its Community Benefits Agreement (CBA).
Image: https://pc.city/chapter-1b-underway/
Luis Diaz, co-founder of PGDx, said the new funding will allow the company to “go out and sell” the cancer diagnostics tech it has been working on for a decade.
Image: Baltimore’s Personal Genome Diagnostics (PGDx) has raised about $214 million in funding to date. CARLEY MILLIGAN
Here’s a look at how Johns Hopkins’ COVID-19 website was created and how it grew visits to more than 38 million in seven months.
Image: https://www.healthcarefinancenews.com
University System of Maryland (USM) asked members of its community to get creative with approaches to educating the public on COVID-19 safety ahead of vaccination.
Among the top submissions: a puppet show, an action film parody and, because this is Maryland, a crab.
USM, which oversees a dozen public higher education campuses in the state, issued a Public Health Challenge through its research and innovation task force in December. It called for videos and images “to highlight how USM students, members of the broader university community, and all Marylanders can stay safe and healthy while waiting for a vaccine.”
Image: From “Pandemic Puppet Fatigue.” (Screenshot via University System of Maryland)
The Montgomery County startup is raising new funding — and eyeing an eventual sale of the business.
Image: Sue Carr designed an alternative to the traditional system used for liquid pharmaceuticals. ANDREW BROOKES
GAITHERSBURG, Md., Feb. 11, 2021 (GLOBE NEWSWIRE) — NexImmune, Inc., a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent and durable immune response that mimics natural biology, today announced the pricing of its upsized initial public offering of 6,471,000 shares of its common stock at a price to the public of $17.00 per share. The gross proceeds to NexImmune from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately $110 million.
Maryland is now one of only six states with more than one university entity spending $1 billion or more per year on research, according to the latest rankings from NSF.
Image: A large portion of Johns Hopkins University’s total research and development spending can be attributed to the school’s Applied Physics Laboratory based in Laurel. COURTESY OF JOHNS HOPKINS APPLIED PHYSICS LABORATORY
